MODULATION SAPP, SAAP ALPHA AND BDNF LEVELS IN INDIVIDUALS DIAGNOSED WITH FXS AND ASD

摘要

A method of treating and monitoring patient diagnosed with Autistic Spectrum disorder or Fragile X syndrome comprising measuring plasma biomarker levels of BDNF, sAPP, and sAPP alpha and adjusting the amount of a therapeutic compound according to the plasma levels of BDNF, sAPP and sAPPs. In one embodiment, the therapeutic compound is acamprosate.